There are currently no medications available that target the YAP-TAZ pathway, which is also active in UM, the cancer-suppressor gene BAP1, or the SF3B1 gene, whose mutations increase the likelihood of metastatic disease (Li et al., 2019). This evidence concerns the gene SF3B1 and cancer.